Page last updated: 2024-08-21

toluene 2,4-diisocyanate and mk 2206

toluene 2,4-diisocyanate has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Cai, S; Cheng, W; Cheng, Y; Cui, H; Dong, J; He, Y; Wang, L; Zhao, H; Zhao, W; Zhou, FH	1

Other Studies

1 other study(ies) available for toluene 2,4-diisocyanate and mk 2206

Article	Year
The AKT inhibitor MK2206 suppresses airway inflammation and the pro‑remodeling pathway in a TDI‑induced asthma mouse model. Molecular medicine reports, 2020, Volume: 22, Issue:5 Topics: Airway Remodeling; Animals; Anti-Inflammatory Agents; Asthma; Cytokines; Dexamethasone; Disease Models, Animal; Heterocyclic Compounds, 3-Ring; Immunoglobulin E; Inflammation; Male; Mice; Mice, Inbred BALB C; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Toluene 2,4-Diisocyanate; Treatment Outcome	2020

Article

Year

The AKT inhibitor MK2206 suppresses airway inflammation and the pro‑remodeling pathway in a TDI‑induced asthma mouse model.

Molecular medicine reports, 2020, Volume: 22, Issue:5

Topics: Airway Remodeling; Animals; Anti-Inflammatory Agents; Asthma; Cytokines; Dexamethasone; Disease Models, Animal; Heterocyclic Compounds, 3-Ring; Immunoglobulin E; Inflammation; Male; Mice; Mice, Inbred BALB C; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Toluene 2,4-Diisocyanate; Treatment Outcome

2020